ExomiR-1260b, derived from non-small cell lung cancer (NSCLC) has been shown to target HIPK2 in human umbilical endothelial cells (HUVECs) and promote the angiogenesis, migration, invasion, and chemoresistance of NSCLC cells [76]. Here, HIPK2 is linked to non-small cell lung carcinoma.